Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled Study to Assess the Effects of Bempedoic Acid (ETC-1002) on the Occurrence of Major Cardiovascular Events in Patients With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant

NCT02993406 is registered in ClinicalTrials.gov with Esperion Therapeutics, Inc. as lead sponsor.

NCT NCT02993406
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02993406 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled Study to Assess the Effects of Bempedoic Acid (ETC-1002) on the Occurrence of Major Cardiovascular Events in Patients With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant
Lead sponsor
Esperion Therapeutics, Inc.
Phase
Phase 3
Overall status
Completed
Start date
December 22, 2016
Completion date
November 7, 2022
Enrollment
13,970 (actual)
Sites
1,319

Conditions

As the registry lists them; a condition with its own page is linked.

cardiovascular diseases, statin adverse reaction